CPNP 2021 industry supported symposia are scientific programs developed for educational purposes. All symposia at CPNP 2021 are designed for the psychiatric pharmacist and are included in participant registration fees. All symposia are in compliance with Accreditation Council for Pharmacy Education (ACPE) criteria for planning and implementation and provide 1.5 contact hours of ACPE credit.

Tuesday, April 20, 1:15-2:45 PM (CDT)

Across the Spectrum: An Update on Bipolar Disorder

Access the Session*

There have been tremendous advances recently in the options available for treating bipolar disorder. In this compelling symposium, we will explore some of those advances and strategies for implementing them into clinical practice. The latest evidence-based diagnostic guidelines and treatments for bipolar depression will be deliberated and investigated. Novel agents and notable achievements in the treatment of disorders across the bipolar spectrum with potential applications from depression with mixed features to psychotic mania will also be discussed.

*Session access will open when the session is live on Tuesday, April 20.

Strategies to Improve Patient Outcomes in Bipolar Depression

Faculty: Roger S. McIntyre, MD, FRCPC

Learning Objectives:

1. Improve recognition and diagnosis of bipolar depression
2. Optimize treatment of depression in the context of bipolar spectrum disorders

Treatment of Bipolar Spectrum Disorders: A Look Towards the Future

Faculty: Stephen M. Stahl, MD, PhD, DSc (Hon.)

Learning Objectives:

1. Contemplate recently published research that may influence the future of mental health care
2. Prepare to implement novel treatment strategies as they become available

Continuing Education

Supported by

Wednesday, April 21, 1:15-2:45 PM (CDT)

Tardive Dyskinesia Across the Complexity Spectrum – From Quality of Life Improvement to Novel Treatments

Click here to register for the symposium or access the webinar/claim CE credit

Tardive dyskinesia (TD) continues to significantly impact patient quality of life, affecting their social and work lives and contributing to high rates of antipsychotic nonadherence. Recent guidelines and expert consensus updates have highlighted the importance of early TD identification for rapid treatment initiation, thus improving patient outcomes. In this program, an expert psychiatrist and pharmacist will provide you with a broader knowledge of TD symptoms across multiple levels of symptom severity, key clinical trial data, and guideline and expert consensus updates.

Presentation Materials

Learning Objectives

• Outline the impact that TD has on patient outcomes, the prevalence of TD in patients currently taking antipsychotic medication, and current barriers to care
• Describe updated recommendations and screening strategies for improved TD recognition across the spectrum of TD severity and symptomatology
• Apply recent guideline updates and knowledge of VMAT2 pharmacology to multidisciplinary TD care plans for patients with mild, moderate, and severe symptomatology

Faculty

Gus Alva, MD, DFAPA

Roger W. Sommi, PharmD, BCPP, FCCP

Continuing Education

In support of improving patient care, NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Provided by

North American Center for Continuing Medical Education (NACCME), LLC, an HMP Global Company

Supported by

Educational grants from Neurocrine Biosciences and Teva Pharmaceuticals